Brokerages Expect EXACT Sciences Co. (EXAS) Will Announce Earnings of -$0.33 Per Share

Wall Street brokerages expect EXACT Sciences Co. (NASDAQ:EXAS) to announce earnings of ($0.33) per share for the current quarter, Zacks reports. Five analysts have made estimates for EXACT Sciences’ earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.38). EXACT Sciences reported earnings of ($0.27) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 22.2%. The business is scheduled to report its next quarterly earnings report on Tuesday, July 24th.

According to Zacks, analysts expect that EXACT Sciences will report full year earnings of ($1.18) per share for the current year, with EPS estimates ranging from ($1.38) to ($1.03). For the next financial year, analysts forecast that the company will post earnings of ($0.35) per share, with EPS estimates ranging from ($0.71) to $0.25. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover EXACT Sciences.

EXACT Sciences (NASDAQ:EXAS) last posted its earnings results on Thursday, April 26th. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.05. The business had revenue of $90.30 million for the quarter, compared to analysts’ expectations of $86.31 million. EXACT Sciences had a negative net margin of 38.61% and a negative return on equity of 20.92%. The business’s revenue for the quarter was up 86.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.32) EPS.

EXAS has been the topic of several research analyst reports. Robert W. Baird upgraded shares of EXACT Sciences from a “neutral” rating to an “outperform” rating and upped their target price for the company from $42.56 to $56.00 in a research note on Tuesday, February 27th. Zacks Investment Research cut shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. BidaskClub cut shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, March 1st. Leerink Swann set a $67.00 target price on shares of EXACT Sciences and gave the company a “buy” rating in a research note on Wednesday, March 28th. Finally, William Blair restated a “buy” rating on shares of EXACT Sciences in a research note on Thursday, March 29th. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $61.05.

EXACT Sciences traded down $2.46, hitting $63.87, during midday trading on Monday, according to Marketbeat.com. 2,628,408 shares of the company traded hands, compared to its average volume of 2,728,286. The company has a debt-to-equity ratio of 0.71, a quick ratio of 14.86 and a current ratio of 15.30. The stock has a market capitalization of $8.09 billion, a P/E ratio of -64.52 and a beta of 0.86. EXACT Sciences has a 52 week low of $33.86 and a 52 week high of $71.60.

In other news, SVP D Scott Coward sold 2,122 shares of the stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $40.12, for a total value of $85,134.64. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Thomas D. Carey sold 8,448 shares of the stock in a transaction that occurred on Tuesday, April 10th. The stock was sold at an average price of $39.73, for a total transaction of $335,639.04. Following the completion of the transaction, the director now owns 52,610 shares in the company, valued at approximately $2,090,195.30. The disclosure for this sale can be found here. Insiders sold a total of 25,204 shares of company stock worth $1,127,639 in the last quarter. Company insiders own 3.20% of the company’s stock.

Large investors have recently modified their holdings of the company. Advisory Services Network LLC lifted its stake in shares of EXACT Sciences by 6,600.0% in the 4th quarter. Advisory Services Network LLC now owns 3,350 shares of the medical research company’s stock worth $176,000 after purchasing an additional 3,300 shares during the period. Quantbot Technologies LP purchased a new stake in EXACT Sciences in the 1st quarter worth approximately $135,000. Bronfman E.L. Rothschild L.P. increased its holdings in EXACT Sciences by 160.8% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,464 shares of the medical research company’s stock worth $140,000 after acquiring an additional 2,136 shares in the last quarter. Probabilities Fund Management LLC purchased a new stake in EXACT Sciences in the 4th quarter worth approximately $210,000. Finally, Jefferies Group LLC purchased a new stake in EXACT Sciences in the 4th quarter worth approximately $230,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply